Medizinische Klinik und Poliklinik I, Universitätsklinikum Bonn.
Dtsch Arztebl Int. 2010 Jul;107(28-29):507-15; quiz 516. doi: 10.3238/arztebl.2010.0507. Epub 2010 Jul 12.
Infection with the human immunodeficiency virus (HIV) remains a major medical challenge.
Selective literature review, including the current German/Austrian, European, and American guidelines on the treatment of HIV infection in adults.
In Germany, 3000 persons become infected with HIV each year; in 2009, 67,000 persons in Germany were living with HIV. When highly active antiretroviral therapy (HAART) is initiated in time, patients can achieve a nearly normal life expectancy. Nonetheless, in Germany as elsewhere, 30% of patients receive the diagnosis of HIV infection only when they have reached the AIDS stage of the disease or are suffering from advanced immunodeficiency. HAART should be started, at the latest, when the CD4-positive helper cell count drops below 350/microL. Primary drug resistances, accompanying illnesses, and the patient's living circumstances must all be taken into account in the selection of antiretroviral drugs. The goal of treatment is lasting suppression of HIV-RNA to below 50 copies per milliliter of plasma.
HIV testing should be offered to all patients at high risk for HIV infection and all persons newly diagnosed with a sexually transmitted disease. As persons with HIV grow older, their treatment is complicated by increasing comorbidity and requires increased vigilance for possible drug interactions.
人类免疫缺陷病毒(HIV)感染仍然是一个主要的医学挑战。
选择性文献回顾,包括目前德国/奥地利、欧洲和美国关于成人 HIV 感染治疗的指南。
在德国,每年有 3000 人感染 HIV;2009 年,德国有 67000 人携带 HIV。当及时开始高效抗逆转录病毒治疗(HAART)时,患者可以实现接近正常的预期寿命。然而,在德国和其他地方一样,30%的患者只有在达到艾滋病阶段或患有晚期免疫缺陷时才被诊断出 HIV 感染。最迟应在 CD4 阳性辅助细胞计数降至每微升 350 以下时开始 HAART。在选择抗逆转录病毒药物时,必须考虑原发性药物耐药性、伴随疾病和患者的生活环境。治疗的目标是将 HIV-RNA 持续抑制到每毫升血浆低于 50 拷贝。
应向所有 HIV 感染高危患者和新诊断为性传播疾病的患者提供 HIV 检测。随着 HIV 感染者年龄的增长,他们的治疗因合并症的增加而变得复杂,需要更加警惕可能的药物相互作用。